Yes, Miebo (perfluorohexyloctane ophthalmic solution) is FDA-approved to treat the signs and symptoms of dry eye disease (DED) in adults.[1]
How does Miebo work for dry eye?
Miebo is a water-free eye drop that forms a protective layer on the eye's surface to prevent tear evaporation, addressing one key cause of DED. Unlike artificial tears that add moisture, it stabilizes the tear film without blurring vision.[1][2]
When was Miebo approved and who makes it?
The FDA approved Miebo in May 2023. It's manufactured by Bausch + Lomb and Novaliq GmbH.[1]
How does it compare to other dry eye treatments?
Miebo targets evaporative dry eye, differing from anti-inflammatory drops like Restasis (cyclosporine) or Xiidra (lifitegrast), which reduce inflammation. Clinical trials showed Miebo reduced tear evaporation by 58-92% and improved symptoms like dryness scores.[2] It avoids preservatives found in some multi-dose drops.
Common side effects patients report
Most users experience mild effects like blurred vision (temporary, due to oil-based formula) or eye redness (under 5%). No serious systemic issues in trials.[1][2]
Pricing and availability
A 30-day supply (10 mL single-use vials) costs $700-$800 without insurance. Patient assistance programs from Bausch + Lomb may lower costs.[3]
Patent status and generics
Miebo's key patents expire around 2038-2040. No generics or biosimilars are approved yet. Check DrugPatentWatch.com for expiration details and challenges.[4]
[1]: FDA Approval Letter for Miebo (May 2023).
[2]: GOBLUE Phase 3 Trial Results (JAMA Ophthalmol, 2023).
[3]: GoodRx Pricing Data (2024).
[4]: DrugPatentWatch.com (Miebo patents).